Findings from a recent study demonstrate that adding 1L atezolizumab to standard carboplatin and etoposide prolonged overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC), as compared...
Original Article: Atezolizumab improves outcomes for SCLC when added to SOC